Ismael_House Posted - 2 days ago

$GSK $TAK LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

HayleyMason__ Posted - 3 days ago

🚨 STOCK ALERT: MYNZ 🚨 🔥 Frankie Muniz is ALL IN—Malcolm in the Middle star & NASCAR #33 driver is now repping MYNZ! 🔎 Petra (ex-Obama advisor) dropped hints about a major U.S. lab partnership—this could be game-changing. 📈 6 news hits in 3 weeks = strong momentum. Something BIG is building here. 🌍 Already solid in the EU market, expanding with insurance-covered tests—this isn’t just hype, it’s execution. 💡 Their test has 88% accuracy, crushing competitors: EXAS (42%) & GH (20%)—clear leader in diagnostics. 💰 $1.5M private placement secured = cash on hand to scale up. 🚀 CEO teasing big plans ahead—keep an eye on this leadership. 📊 New offering deal + TMO partnership = validation and growth catalysts. ⚡ MYNZ is ticking all the boxes for a breakout! Don’t let this one fly under your radar! 💥 $GSK $TAK $ALNY

MaisieGuerrero Posted - 6 days ago

😏🚀 MYNZ We know the date of the reverse split (RS) if there will be one, but possibly a Nasdaq extension will be granted. Last time it traded, 50 million and 19 million heavy shorts attacked. Now, it has huge credibility after the TMO partnership and the meeting. The company will decide by November 25th whether or not to do an RS based on Nasdaq's response. Anyway, after the RS, I'm not worried about what happens next. A $210 billion partner TMO signing a deal with a penny stock has never happened before. I will be loading heavy on Monday. This will go to the moon like the DRUG stock recently did. The price target (PT) is $50. The squeeze will be parabolic. $GSK $TAK

Benzinga Posted - 1 week ago

AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients https://www.benzinga.com/general/biotech/24/11/41977487/ac-immunes-active-immunotherapy-shows-antibody-responses-in-early-parkinsons-patients $ACIU $TAK

biotech Posted - 1 week ago

Barlays $SGMO intention to outlicense #Fabry, with ongoing late-stage discussion with potential partners. #Deal likely could be #announced in near term. We continued to see high prob of positive data and approval. Reiterate OW and increase PT to $9 to reflect Fabry program update $PFE $RHHBY $TAK $AZN

RodneyPerry Posted - 2 weeks ago

🚨 MYNZ HUGE PR drop incoming before the Nov 13 meeting 🔥 Someone is pushing these dates of upcoming NEWS 3 biggest stock alert channels announced, might consider to add now, who knows. $GSK $TAK

ClarkK1982C Posted - 2 weeks ago

$GSK $TAK MYNZ +10.91% PM LFG, unusually high volume activity last week, apx 30% more than average. 👇😘🚀 This stock may see the last time this price per share PT $5+ 🚀 HUGE PRs drop incoming before the Nov 13 meeting, so compliance is coming—no RS needed. Here is why… 1.Frankie Muniz backing Mainz (yes, the Malcolm guy & NASCAR #33 now repping MYNZ). 2.Petra, ex-Obama advisor, hinted at a big U.S. lab partner. Solid source! 3.Six news hits in 3 weeks—momentum. 4.Already solid in the EU, not new but expanding, with insurance covering their tests. 5.Their test has 88% accuracy vs. EXAS (42%) & GH (20%)—big edge! 6.$1.5M private placement in the bag. 7.CEO teased big plans ahead.

equips Posted - 3 weeks ago

$TAK What is the relationship between meeting the revenue expectation and the price of the stock?

irav Posted - 10/31/24

$TAK https://www.takeda.com/newsroom/newsreleases/2024/notice-of-the-revised-forecast-of-consolidated-financials-for-fy2024-ifrs/

Estimize Posted - 10/28/24

Wall St is expecting 7,452 revenue for $TAK Q2 [Reporting 10/31 BMO] http://www.estimize.com/intro/tak?chart=historical&metric_name=revenue

SparkyReturns Posted - 10/24/24

$GSK So, I did not expect this much strength with XERIS. But there it is. I thought it was going to bounce around $3.00 much longer than it has so far. Maybe the news is starting to get out about how undervalued this is due to XP-8121 going into Ph III soon, and the big pharma collaborations with Regeneron and Amgen and others which have the potential for scalability and big milestones and royalties. Its amazing that Xeriject requires no refrigeration and can be used with large molecule MAbs and so many existing drugs for SubQ administration, instead of lengthy infusions. Amgen even recently stopped a study with Halo and decided to go with Xeriject instead. CF+ next year should start to get everyone's attention. Cheers! $BAYRY $TAK $ALXN

Quantumup Posted - 1 month ago

H.C. Wainwright🏁 $ALMS Buy/$30, says 'A best-in-class TYK2 inhibitor, risk-mitigated by impressive clinical data and by commercial-stage Sotyktu.' W/in the TYK2 arena, ESK-001 has the highest selectivity for the TYK2🎯besting $BMY Sotyktu and $TAK TAK-279. ESK-001=much >profile vs Sotyktu:

SparkyReturns Posted - 1 month ago

$XERS If you believe in the company, buy all dips whenever you can. I have been buying for 3 years for these reasons: 2 products' revenue keeps growing and Keveyis nicely stable despite generic. Big Pharma collabs on deck will be worth tens of millions easily, potentially 100M over a few years. XP-8121 easily worth $1B-2B, will be the ONLY subQ option for people on Levo with gastro issues and should rapidly capture market share. The 3 products have some competition but theirs seem to be best in class. Delivery technology - SCALABILITY - we are just getting started. Little government risk. A while back people were moaning about Rx caps, but congress would only cap big pharma, not small bios with innovative products. Ample cash to bring them to CF+. This is not an overnight success or a stock to flip, but, its a stock you can load up on and know that eventually it will pay off handsomely and for people willing to stay in a few years, multi-bagger with little risk. $PFE $REGN $GILD $TAK

Quantumup Posted - 1 month ago

TD Cowen reiterated $PTGX Buy/$65. TD Cowen said in its research note: We hosted meetings with Protagonist management to discuss the Q4 Phase III data in PsO, where the 200mg QD dose was clearly the best choice and 2113 could address at least 2M patients. UC is the main focus of investors, and 2113 does not need to beat injectables. Rusfertide can address a multi-billion dollar market, too. Oral IL-17 and obesity assets could also generate excitement and upside. $JNJ $tak

Posporino Posted - 1 month ago

@Broview for that you’d need to buy and hold the Japanese stock $4502.T, not $TAK. TAK ADS stock is 1/2 of a 4502.T, so the attractive dividend of Takeda is sliced to half for the ADS owners.

DonCorleone77 Posted - 1 month ago

$TAK $ALPMY $SMFG Takeda, Astellas Pharma and Sumitomo Mitsui form early drug discovery JV Ciconia Bioventures announced its establishment as a joint venture, or JV, company based on a master agreement signed on April 22 by Takeda Pharmaceutical (TAK), Astellas Pharma (ALPMY), and Sumitomo Mitsui Banking Corporation (SMFG). Ciconia covers the entire process from early drug discovery research to establishment of biotech startups, with the aim of translating innovative technologies and drug discovery programs originating in Japan into clinical applications.

DonCorleone77 Posted - 1 month ago

$GLTO $TAK Galecto completes strategic review, will focus on oncology, liver disease Galecto (GLTO) announced that, following an intensive strategic review process, Galecto has determined to focus on cancer and liver disease, leveraging its existing clinical stage asset GB1211, which has shown positive results in non-small cell lung cancer and decompensated cirrhosis clinical studies. Galecto further announced that it has bolstered its pipeline with the acquisition of the global rights to BRM-1420, a novel, first-in-class asset developed by Bridge Medicines, a company co-founded by Takeda (TAK). "Our strategic review process concluded that our best opportunity for building value and changing the lives for patients with severe diseases was to focus on our existing clinical stage compound GB1211 and increase our chance for success by acquiring complementary assets. The addition of BRM-1420 represents a significant advancement in our mission to develop and deliver breakthrough treatments for oncology and liver conditions," said Dr. Hans Schambye, CEO of Galecto. "We are particularly optimistic about BRM-1420's potential to address challenging genetic subsets of AML and its observed synergistic effects with standard-of-care therapies and menin inhibitors." As consideration for the acquisition of the global rights of BRM-1420, Galecto issued 62,594 shares of common stock to Bridge Medicines, representing 4.99% of the outstanding shares of Galecto's common stock as of the date of the asset purchase, and 160.562 shares of a newly-issued Series A preferred stock convertible into 160,562 shares of common stock, or approximately 12.8% of Galecto's common stock, upon receipt of stockholder approval. Matthew Kronmiller, Bridge Medicine's Chief Executive Officer, will be joining Galecto's management team as the Executive Vice President of Strategy and Chief Business Officer. The transaction was approved by the Boards of Directors of both companies.

Broview Posted - 1 month ago

$TAK hold for dividend. Japanese getting old, they need medicine?

stiselini Posted - 09/30/24

$TAK Sold on technical sell signal being comfirmed

CO_ISO_37301 Posted - 09/28/24

$TAK 🔈🔉🔊 Daughter - Medicine (Sound Remedy Remix) https://on.soundcloud.com/Y9FamgZzR3CqqapK6

Stock_Titan Posted - 09/26/24

$TEM $TAK Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development https://www.stocktitan.net/news/TEM/tempus-announces-expansion-of-collaboration-with-takeda-to-leverage-cb9mzgg1pgx5.html

Stock_Titan Posted - 09/24/24

$TAK Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer https://www.stocktitan.net/news/TAK/takeda-receives-approval-for-fruzaqla-fruquintinib-in-japan-for-the-t5v9bt7lo03w.html

briefingcom Posted - 2 months ago

$TAK: UK MHRA approved the new medicine fruquintinib (Fruzaqla) to treat adult patients with metastatic colorectal cancer https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240920082741TAK&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

briefingcom Posted - 2 months ago

$TAK: Takeda to present additional clinical trial study data highlighting the impact of Orexin agonist TAK-861 on the burden of narcolepsy at Sleep Europe 2024 https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240919080410TAK&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

Stock_Titan Posted - 2 months ago

$TAK Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024 https://www.stocktitan.net/news/TAK/takeda-to-present-additional-clinical-trial-study-data-highlighting-xcn3gxhl44b1.html

JuggernautRaider Posted - 2 months ago

Buy $RDHL HOLD $LLY Sell $TAK

DMAY0 Posted - 2 months ago

$PHAT ❤️🇺🇸 $TAK for a hold until dividend. Let’s keep it up!!!!!!

WOLFSTREET Posted - 2 months ago

$TAK UP!, Slow mover but pays dividend and it's going Up! "Get Your ➺ CC🧭 On"

DMAY0 Posted - 2 months ago

$BDX I missed this in sorts of dividend payout, but still a great buy. Looking how too shift over. $VALE just paid and I have my eye on $TAK for future dividend/ stock growth play. $PHAT still my favorite stock

DMAY0 Posted - 2 months ago

$TAK have my eye on $TAK $PHAT friends. Won’t be as much of a growth, but pays a nice dividend if bought before 9/29.